https://www.selleckchem.com/products/r428.html
1, 95% CI 0.99-4.67, p = 0.04). In the group that only received radiotherapy (RT), CpG1 and CpC3 methylations were found to have a positive prognostic significance in terms of PFS (OR 266, 95% CI 1.05-6.75, p -0.03 for CpG1; OR 2.4, 95% CI 1.01-5.92, p = 0.04 for CpG3). The MGMT promoter methylation represents an important biomarker for predicting response to therapy. Individual islands, particularly CpG3, deserves further investigation as a prognostic marker. Further studies need to be done with larger sample sizes to clarify the results.
Aimer
Commentaire
Partagez
